Buprenorphine Transdermal System for Opioid Therapy in Patients with Chronic Low Back Pain

Simple item page
dc.contributor.authorGordon, Allan
dc.contributor.authorRashiq, Saifudin
dc.contributor.authorMoulin, Dwight E
dc.contributor.authorClark, Alexander J
dc.contributor.authorBeaulieu, André D
dc.contributor.authorEisenhoffer, John
dc.contributor.authorPiraino, Paula S
dc.contributor.authorQuigley, Patricia
dc.contributor.authorHarsanyi, Zoltan
dc.contributor.authorDarke, Andrew C
dc.date.accessioned2018-09-27T12:05:59Z
dc.date.available2018-09-27T12:05:59Z
dc.date.issued2010-01-01
dc.date.updated2018-09-27T12:05:59Z
dc.description.abstractOBJECTIVE: The present randomized, double-blinded, crossover study compared the efficacy and safety of a seven-day buprenorphine transdermal system (BTDS) and placebo in patients with low back pain of moderate or greater severity for at least six weeks.METHODS: Prestudy analgesics were discontinued the evening before random assignment to 5 μg/h BTDS or placebo, with acetaminophen 300 mg/codeine 30 mg, one to two tablets every 4 h to 6 h as needed, for rescue analgesia. The dose was titrated to effect weekly, if tolerated, to 10 μg/h and 20 μg/h BTDS. Each treatment phase was four weeks.RESULTS: Fifty-three patients (28 men, 25 women, mean [± SD] age 54.5±12.7 years) were evaluable for efficacy (completed two weeks or more in each phase). Baseline pain was 62.1±15.5 mm (100 mm visual analogue scale) and 2.5±0.6 (five-point ordinal scale). BTDS resulted in lower mean daily pain scores than in the placebo group (37.6±20.7 mm versus 43.6±21.2 mm on a visual analogue scale, P=0.0487; and 1.7±0.6 versus 2.0±0.7 on the ordinal scale, P=0.0358). Most patients titrated to the highest dose of BTDS (59% 20 μg/h, 31% 10 μg/h and 10% 5 μg/h). There were improvements from baseline in pain and disability (Pain Disability Index), Pain and Sleep (visual analogue scale), Quebec Back Pain Disability Scale and Short-Form 36 Health Survey scores for both BTDS and placebo groups, without significant differences between treatments. While there were more opioid-related side effects with BTDS treatment than with placebo, there were no serious adverse events. A total of 82% of patients chose to continue BTDS in a long-term open-label evaluation, in whom improvements in pain intensity, functionality and quality of life were sustained for up to six months without analgesic tolerance.CONCLUSION: BTDS (5 μg/h to 20 μg/h) represents a new treatment option for initial opioid therapy in patients with chronic low back pain.
dc.description.versionPeer Reviewed
dc.identifier.citationAllan Gordon, Saifudin Rashiq, Dwight E Moulin, et al., “Buprenorphine Transdermal System for Opioid Therapy in Patients with Chronic Low Back Pain,” Pain Research and Management, vol. 15, no. 3, pp. 169-178, 2010. doi:10.1155/2010/216725
dc.identifier.doihttps://doi.org/10.1155/2010/216725
dc.identifier.urihttp://hdl.handle.net/1880/108471
dc.language.rfc3066en
dc.rights.holderCopyright © 2010 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.titleBuprenorphine Transdermal System for Opioid Therapy in Patients with Chronic Low Back Pain
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
PRM.2010.216725.pdf
Size:
569.56 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications